Concord Medical Services Holdings stock faces a two year restatement

Concord Medical Services Holdings stock is tied to a two year financial restatement after the company said its 2024 and 2025 accounts should no longer be relied upon. The disclosure dated September 22, 2026 also names a new auditor and a material weakness in financial reporting.

Two fiscal years face revision

According to StockTitan, the company plans to restate the financial statements for fiscal years 2024 and 2025 after SEC staff questioned whether Concord Medical retained control of Concord Healthcare Group in 2024. The filing therefore covers two fiscal years rather than one, making the accounting correction broader than a single-period adjustment.

The company intends to file an amended Form 20-F for fiscal year 2025. The restatement is designed to deconsolidate Concord Healthcare Group from 2024, which could change the reported scale of revenue, assets and liabilities in the affected accounts.

Auditor change adds pressure

The SEC records the Form 6-K filing on September 22, 2026 for Concord Medical Services Holdings Ltd. The filing states that Shandong Haoxin resigned as independent auditor on September 14, 2026, while Guangdong Prouden CPAs GP was engaged on September 22, 2026.

The filing also identifies a material weakness linked to limited staff and resources with appropriate U.S. GAAP and SEC reporting expertise. For investors, the central issue is the reliability of the historical accounts and the timing of the amended filing, not simply the change of audit firm.

NYSE valuation stays small

Concord Medical Services Holdings was last quoted at USD 3.32 on the NYSE on September 29, 2026. Its 52-week range was USD 3.18 to USD 6.96, while market capitalization stood at USD 9.4 million on the same date.